Astral raises £23M for medical isotope supply
Bristol-based Astral Systems raised £23M to advance compact fusion technology for producing medical radioisotopes.
Medical radioisotopes are a quiet but critical part of cancer diagnosis and treatment. Astral Systems is trying to make that supply chain more resilient with compact fusion technology.
What happened
Bristol-based Astral Systems raised £23M to advance its compact fusion-reactor technology for producing medical radioisotopes.
These isotopes are used in cancer diagnosis and treatment, and the company is working toward clinical trials in early 2027.
Why it matters
This is a strong life sciences and deeptech crossover.
Medical radioisotopes are supply-constrained, while many traditional production systems rely on ageing fission reactors. If Astral can produce isotopes through compact fusion systems, it could create a more reliable supply chain for targeted cancer therapies.
The bigger picture
Some of the most important deeptech companies will not look like software startups. They will sit inside hard infrastructure problems where better physics can unlock better healthcare, energy or industrial resilience.